Monoclonal Antibodies That Mimic the Action of Intravenous Immunoglobulin Can Inhibit Immune Thrombocytopenia

Publication
Article
OncologyONCOLOGY Vol 16 No 3
Volume 16
Issue 3

Intravenous immunoglobulin (IVIG) is prepared from large pools of plasma from healthy donors and is widely used to treat autoimmune diseases, especially immune thrombocytopenic purpura (ITP). Human polyclonal antierythrocyte antibodies, such as anti-D, can also be effective at treating ITP in individuals expressing the appropriate antigen. The demand for IVIG and anti-D exceeds the supply, and the development of a recombinant product to replace these human-derived blood products would be highly desirable. We have hypothesized that monoclonal antibodies directed against red cells may be effective in inhibiting immune forms of thrombocytopenia.

 

Intravenous immunoglobulin (IVIG) is prepared from large pools of plasma from healthy donors and is widely used to treat autoimmune diseases, especially immune thrombocytopenic purpura (ITP). Human polyclonal antierythrocyte antibodies, such as anti-D, can also be effective at treating ITP in individuals expressing the appropriate antigen. The demand for IVIG and anti-D exceeds the supply, and the development of a recombinant product to replace these human-derived blood products would be highly desirable. We have hypothesized that monoclonal antibodies directed against red cells may be effective in inhibiting immune forms of thrombocytopenia.

Mice were individually injected with 50 mg of human IVIG (2 g IVIG/kg body weight) vs 50 µg, 5 µg, or 0.5 µg of an antibody specific for the TER-119 erythrocyte antigen as well as two antibodies against the heat-stable antigen (CD24) found on erythrocytes. After 24 hours, the mice were treated with antiplatelet (anti-GPIIb) antibody. Thrombocytopenia was assessed after a further 24 hours by flow cytometry. Standard human IVIG prevented thrombocytopenia, as expected. The monoclonal antibody specific for the TER-119 antigen and one of the anti-CD24-specific antibodies inhibited thrombocytopenia almost as well as IVIG at a 1,000× lower dose than IVIG. The antibodies that did inhibit thrombocytopenia significantly blocked reticuloendothelial system (RES) function but not the anti-CD24 antibody, which did not inhibit thrombocytopenia.

To determine if a monoclonal antibody that blocks RES function (anti-FcgR) vs those that bind/block complement receptors could also inhibit thrombocytopenia, we examined the effect of an antibody to FcgRII/III (2.4G2) as well as two antibodies directed to complement receptors 1, 2, and 3. Only the blocking anti-FcgRII/III antibody, but neither of the antibodies specific for the complement receptors, inhibited thrombocytopenia.

CONCLUSION: It is proposed that IVIG and/or polyclonal anti-D could be replaced by monoclonal antibodies directed to red cells in the treatment of ITP.

Recent Videos
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.
Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.